Last reviewed · How we verify
Ped3CB
Ped3CB is a small molecule that acts as a selective inhibitor of the sodium- potassium pump.
Ped3CB is a small molecule that acts as a selective inhibitor of the sodium- potassium pump. Used for Hypertension, Heart failure.
At a glance
| Generic name | Ped3CB |
|---|---|
| Sponsor | Baxter Healthcare Corporation |
| Drug class | Sodium-potassium pump inhibitor |
| Target | Na+/K+-ATPase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the sodium-potassium pump, Ped3CB reduces the activity of the pump, which can help to reduce blood pressure and alleviate symptoms of heart failure.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Hypokalemia
- Nausea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ped3CB CI brief — competitive landscape report
- Ped3CB updates RSS · CI watch RSS
- Baxter Healthcare Corporation portfolio CI